Blue Earth Diagnostics has entered a distribution partnership for fluciclovine with Norsk Medisinsk Syklotronsenter (NMS) to cover the Norwegian territory.
Blue Earth Diagnostics already has submitted an application to the European Medicines Agency for European Union marketing clearance for its fluciclovine (F-18) radiopharmaceutical for lesion detection and localization for prostate cancer patients with biochemical recurrence. If Blue Earth receives clearance, NMS will be responsible for the manufacture, distribution, and sale of the product to clinical imaging centers in Norway.
F-18 is a synthetic, amino acid, investigational, PET radiopharmaceutical being investigated in the imaging of various cancers, with its lead application in prostate cancer.
